通过增强纤溶作用治疗腿部脂肪硬化症：初步报告
Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report.
作者信息
Browse N L, Jarrett P E, Morland M, Burnand K
出版信息
Br Med J. 1977 Aug 13;2(6084):434-5. doi: 10.1136/bmj.2.6084.434.
Abstract
Fourteen patients with longstanding lipodermatosclerosis of their lower legs, secondary to venous disease in 11, were treated for three months with stanozolol, a drug that enhances fibrinolytic activity. No other treatment was given and no change made in existing treatment. All the patients improved. Two were cured in three months, three were able to stop treatment in the next three to 11 months, and the other nine continued to improve. Fibrinolytic enhancement, with stanozolol, seems to be a worthwhile addition to the treatment of venous liposclerosis and deserves further study.
摘要
14名小腿患有长期脂性皮肤硬化症的患者，其中11例继发于静脉疾病，接受司坦唑醇治疗3个月，司坦唑醇是一种可增强纤溶活性的药物。未给予其他治疗，现有治疗也未改变。所有患者均有改善。2例在3个月内治愈，3例在接下来的3至11个月内能够停止治疗，另外9例持续改善。司坦唑醇增强纤溶活性，似乎是静脉性脂肪硬化症治疗中一项值得添加的治疗方法，值得进一步研究。
相似文献
1
Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report.通过增强纤溶作用治疗腿部脂肪硬化症：初步报告
Br Med J. 1977 Aug 13;2(6084):434-5. doi: 10.1136/bmj.2.6084.434.
2
Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression.静脉性脂皮硬化症：通过增强纤溶作用和弹性压迫进行治疗。
Br Med J. 1980 Jan 5;280(6206):7-11. doi: 10.1136/bmj.280.6206.7.
3
Stanozolol as a novel therapeutic agent in dermatology.司坦唑醇作为皮肤科的一种新型治疗药物。
J Am Acad Dermatol. 1995 Aug;33(2 Pt 1):254-8. doi: 10.1016/0190-9622(95)90244-9.
4
Treatment of liposclerosis.脂性硬化的治疗。
Br Med J. 1980 Jan 26;280(6209):254-5. doi: 10.1136/bmj.280.6209.254-d.
5
Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial.使用原型合成代谢类固醇（司坦唑醇）治疗脂性皮肤硬化症和静脉溃疡患者的肝酶和血脂水平：一项前瞻性、随机、双盲、安慰剂对照试验。
Int J Low Extrem Wounds. 2015 Mar;14(1):11-8. doi: 10.1177/1534734614562276. Epub 2015 Feb 3.
6
Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency.司坦唑醇增强纤溶作用治疗静脉功能不全的疗效
Aust N Z J Surg. 1991 Apr;61(4):306-9. doi: 10.1111/j.1445-2197.1991.tb00217.x.
7
Fibrinolytic enhancement with stanozolol fails to improve symptoms and signs in patients with post-surgical back pain.司坦唑醇增强纤溶作用未能改善手术后背痛患者的症状和体征。
Scand J Rheumatol. 1991;20(6):414-8. doi: 10.3109/03009749109096820.
8
Beta-methasone-17-valerate in the topical treatment of hypostatic leg eczema.倍他米松-17-戊酸酯用于坠积性腿部湿疹的局部治疗。
Angiology. 1969 Jan;20(1):27-32. doi: 10.1177/000331976902000104.
9
Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.特发性复发性浅表血栓性静脉炎：纤维蛋白溶解增强疗法。
Br Med J. 1977 Apr 9;1(6066):933-4. doi: 10.1136/bmj.1.6066.933.
10
Treatment of Raynaud's phenomenon by fibrinolytic enhancement.通过增强纤溶作用治疗雷诺现象。
Br Med J. 1978 Aug 19;2(6136):523-5. doi: 10.1136/bmj.2.6136.523.
引用本文的文献
1
Venous leg ulcer: Systemic therapy.下肢静脉溃疡：全身治疗。
Indian Dermatol Online J. 2014 Jul;5(3):374-7. doi: 10.4103/2229-5178.137821.
2
Management of leg ulcers.腿部溃疡的管理
Postgrad Med J. 2000 Nov;76(901):674-82. doi: 10.1136/pmj.76.901.674.
3
Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration.腿部溃疡皮肤周围的毛细血管纤维蛋白：脂膜皮肤硬化症和静脉溃疡的病因。
Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1071-2. doi: 10.1136/bmj.285.6348.1071.
4
Venous ulceration.静脉溃疡
Br Med J (Clin Res Ed). 1983 Jul 30;287(6388):356-7. doi: 10.1136/bmj.287.6388.356-a.
5
Venous ulceration.静脉溃疡
Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1920-2. doi: 10.1136/bmj.286.6382.1920.
6
Systemic sclerosis--a microvascular disorder?系统性硬化症——一种微血管疾病？
J R Soc Med. 1983 Aug;76(8):635-42. doi: 10.1177/014107688307600804.
7
The etiology of venous ulceration.静脉溃疡的病因。
World J Surg. 1986 Dec;10(6):938-43. doi: 10.1007/BF01658644.
8
Drug treatment of chronic venous insufficiency and venous ulceration: a review.慢性静脉功能不全和静脉溃疡的药物治疗：综述
J R Soc Med. 1991 Jun;84(6):354-8. doi: 10.1177/014107689108400616.
9
A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.司坦唑醇治疗原发性雷诺现象和系统性硬化症的对照研究。
Ann Rheum Dis. 1991 Jan;50(1):41-7. doi: 10.1136/ard.50.1.41.
10
Leg ulceration in venous disease.静脉疾病中的腿部溃疡
Postgrad Med J. 1992 Oct;68(804):779-85. doi: 10.1136/pgmj.68.804.779.
本文引用的文献
1
Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis.昼夜纤维蛋白溶解节律的证据；采用一种测量自然纤维蛋白溶解的简单方法。
Clin Sci. 1957 Nov;16(4):645-50.
2
The fibrin plate method for estimating fibrinolytic activity.用于评估纤维蛋白溶解活性的纤维蛋白平板法。
Arch Biochem Biophys. 1952 Oct;40(2):346-51. doi: 10.1016/0003-9861(52)90121-5.
3
Fibrinolytic enhancement by stanozolol: a double blind trial.
Br J Haematol. 1972 May;22(5):543-59.
4
Proceedings: Extravascular fibrin deposition in response to venous hypertension-the cause of venous ulcers.
Br J Surg. 1976 Aug;63(8):660-1.
5
Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.特发性复发性浅表血栓性静脉炎：纤维蛋白溶解增强疗法。
Br Med J. 1977 Apr 9;1(6066):933-4. doi: 10.1136/bmj.1.6066.933.
6
Blood and vein-wall fibrinolytic activity in health and vascular disease.健康与血管疾病状态下的血液及血管壁纤溶活性
Br Med J. 1977 Feb 19;1(6059):478-81. doi: 10.1136/bmj.1.6059.478.
Zotero 插件